With a one year PEG ratio of 0.51, Happiness Biotech Group Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 6.17% of US stocks.
HAPP's went public 1.1 years ago, making it older than only 0.72% of listed US stocks we're tracking.
HAPP's current price/earnings ratio is 3.84, which is higher than merely 2.75% of US stocks with positive earnings.
Stocks with similar financial metrics, market capitalization, and price volatility to Happiness Biotech Group Ltd are UG, BHAT, GIGM, JOUT, and SCON.
HAPP's SEC filings can be seen here. And to visit Happiness Biotech Group Ltd's official web site, go to www.happ.org.cn.
Happiness Biotech Group Ltd. is a nutraceutical and dietary supplements producer, which engages in the research, development, manufacturing, marketing, and sales of a variety of products made from herbal and animal extracts. The firm's products include lucidum spore powder; cordyceps mycelia; ijiao solution; and American ginseng. It operates under the brand name Happiness. The company was founded on February 9, 2018 and is headquartered in Nanping City, China.
HAPP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Happiness Biotech Group Ltd. To summarize, we found that Happiness Biotech Group Ltd ranked in the 30th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Happiness Biotech Group Ltd, consider:
The compound growth rate in the free cash flow of Happiness Biotech Group Ltd over the past 1.08 years is -0.23%; that's higher than just 7.51% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 14.09% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
PCRX, HSIC, CDNA, IONS, and JNJ can be thought of as valuation peers to HAPP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Happiness Biotech ([[HAPP]] +15.5%) entered into a certain securities purchase agreement with three non-U.S. investors under which it has agreed to sell 900K ordinary shares at $2.5/share.Gross proceeds to be used for the development of Happy Buy's B2B e-Commerce business as well as for working capital and general corporate use."In addition to the capital,...
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company has declared a cash dividend of $0.015 per ordinary share, payable in cash on or about August 17, 2020, to shareholders of record on August 10, 2020.
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, today announced its financial results for the fiscal year ended March 31, 2020.
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the 75% Alcohol Disposable Hand Sanitizer from the Company has successfully obtained Natural Product Number (NPN) license from Health Canada and the first order of 53,280 bottles have been shipped this week.